On this page

Desonide Ointment, 0.05%

Prescription ANDA TE AB Official labelling
Informational index, not medical advice. Content is reproduced from public FDA and NLM data. Always confirm against the manufacturer's current prescribing information. Report adverse events to FDA MedWatch.

Overview

Brand name
Desonide Ointment, 0.05%
Generic name
Desonide Ointment, 0.05%
Dosage form
Ointment
Route
Topical
Marketing category
ANDA · ANDA
Labeler
Bryant Ranch Prepack
Product type
Human Prescription Drug
DEA schedule
Not scheduled
Active ingredients
1
NDC product codes
4
Packages
6
Data completeness
76% of corroborating sources present

Active ingredients

Source: NDC Directory
Active ingredients and strengths as listed in the NDC Directory.
Ingredient Strength RxCUI Monograph
Desonide .5 mg/g 204135 View

Forms, strengths and routes

Source: NDC Directory
Dosage form
Ointment
Route of administration
Topical
Presentations
10

Pharmacologic classes are listed in the class section below.

Pharmacologic class

Source: NDC Directory
Established pharmacologic classes (EPC), mechanisms of action (MoA), chemical structures (CS) and physiologic effects (PE).
Class Type Browse
Corticosteroid Hormone Receptor Agonists [MoA] MoA All 215 members
Corticosteroid [EPC] EPC All 215 members

Regulatory status

Source: Drugs@FDANDC Directory
Application number
210998
Application type
ANDA · Abbreviated New Drug Application
Approval date
January 30, 2019
Sponsor
ENCUBE ETHICALS
Products on application
1
Submissions recorded
1
Products approved under application 210998.
Product Trade name Form Strength Ingredient Status TE Flags
210998-001 DESONIDE OINTMENT DESONIDE Prescription AB

Therapeutic equivalence

Source: Orange Book
TE code
AB
Reference Listed Drug
No
Reference Standard
No

What this rating means: Therapeutically equivalent — bioequivalence demonstrated by in vivo or in vitro testing

Codes beginning with “A” indicate products the FDA considers therapeutically equivalent. Codes beginning with “B” indicate bioequivalence has not been established. See methodology.

Approval history

Source: Drugs@FDA
Most recent submissions on application 210998.
Type No. Action Status Date Review
Original application 1 Approved January 30, 2019 Standard

Prescribing information

Source: openFDA Drug Labeling

Reproduced verbatim from the Structured Product Labeling submitted to the FDA (effective 20260528). This is the manufacturer's labelling text, not a summary and not advice.

HUMAN PRESCRIPTION DRUG · 20260528 HUMAN PRESCRIPTION DRUG · 20260309

Indications and Usage

openFDA Drug Labeling

INDICATIONS AND USAGE Desonide ointment USP, 0.05% is a low potency corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses. It should not be used for longer than two weeks unless directed by a physician.

Dosage and Administration

openFDA Drug Labeling

DOSAGE AND ADMINISTRATION Desonide Ointment, 0.05% should be applied to the affected area as a thin film from two to four times daily depending on the severity of the condition. As with other corticosteroids, therapy should be discontinued when control is achieved. If no improvement is seen within two weeks, reassessment of diagnosis may be necessary. Desonide Ointment, 0.05% should not be used with occlusive dressings.

Contraindications

openFDA Drug Labeling

CONTRAINDICATIONS Desonide Ointment, 0.05% is contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.

Adverse Reactions

openFDA Drug Labeling

ADVERSE REACTIONS In controlled clinical trials, the total incidence of adverse reactions associated with the use of Desonide Ointment, 0.05% was approximately 6%. These adverse reactions were erythema, induration, pruritus, irritation, oiliness, and peripheral edema. The following additional local adverse reactions have been reported infrequently with topical corticosteroids, and they may occur more frequently with the use of occlusive dressings and higher potency corticosteroids. These reactions are listed in approximate decreasing order of occurrence: dryness, folliculitis, acneiform eruptions, perioral dermatitis, allergic contact dermatitis, secondary infection, skin atrophy, striae, miliaria, burning and hypopigmentation. To report SUSPECTED ADVERSE REACTIONS , contact Encube Ethicals Private Limited at 1-833-285-4151 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Description

openFDA Drug Labeling

DESCRIPTION Desonide ointment USP, 0.05% contains desonide (Pregna-1,4-diene-3,20-dione,11,21-dihydroxy-16,17-[(1-methylethylidene)bis(oxy)]-,(11ß,16α)) a synthetic corticosteroid for topical dermatologic use. The corticosteroids constitute a class of primary synthetic steroids used topically as anti-inflammatory and antipruritic agents. Chemically, desonide, the active ingredient in desonide ointment USP, 0.05% is C 24 H 32 O 6 . It has the following structural formula: The molecular weight of desonide is 416.51. It is white to off-white powder. The solubility of desonide in distilled water saturated with the ether is 184 mg/L. Each gram of desonide ointment USP, 0.05% contains 0.5 milligram of desonide microdispersed in a base of white petrolatum. structure.jpg

OVERDOSAGE Topically applied Desonide Ointment, 0.05% can be absorbed in sufficient amounts to produce systemic effects (see PRECAUTIONS ).

How Supplied / Storage and Handling

openFDA Drug Labeling

HOW SUPPLIED Desonide ointment USP, 0.05% is available as follows: 15 g tube (NDC 21922-004-04) 60 g tube (NDC 21922-004-07) STORAGE Store at 20°C to 25°C (68°F to 77°F) [see USP Controlled Room Temperature]. Product of Italy Manufactured by: Encube Ethicals Pvt. Ltd. Plot No. C1, Madkaim Industrial Estate, Madkaim, Post Mardol, Ponda, Goa-403 404, India. Distributed by: Encube Ethicals, Inc. 200 Meredith Drive, Suite 202, Durham, NC 27713 USA Rev. 11/25

Adverse event reports

Source: openFDA FAERS
4,961
FAERS reports mentioning this drug
as of 2026-09-25T03:42:24+00:00
A report count is not a risk measure. FAERS accepts voluntary and mandatory reports without establishing causation, and reporting is influenced by how widely a drug is used, how long it has been marketed, and media attention. FDA states that reports “do not prove that the drug caused the event”. Compare rates, not totals.

Attributed to this product's most-reported active ingredient: DESONIDE. Combination products with more than six active ingredients are not attributed, because a report count summed across a long ingredient list measures the list, not the medicine.

Packaging and NDCs

Source: NDC Directory
Every National Drug Code package associated with this medication. The NDC is the identifier used for dispensing, billing and pharmacovigilance in the United States.
Package NDC Product NDC Labeler Description Marketing start
63629-8481-1 63629-8481 Bryant Ranch Prepack 1 TUBE in 1 CARTON (63629-8481-1) / 60 g in 1 TUBE March 20, 2019
63629-8482-1 63629-8482 Bryant Ranch Prepack 1 TUBE in 1 CARTON (63629-8482-1) / 15 g in 1 TUBE March 20, 2019
72162-1272-2 72162-1272 Bryant Ranch Prepack 1 TUBE in 1 CARTON (72162-1272-2) / 15 g in 1 TUBE March 20, 2019
72162-1272-6 72162-1272 Bryant Ranch Prepack 1 TUBE in 1 CARTON (72162-1272-6) / 60 g in 1 TUBE March 20, 2019
21922-004-04 21922-004 Encube Ethicals, Inc. 1 TUBE in 1 CARTON (21922-004-04) / 15 g in 1 TUBE March 20, 2019
21922-004-07 21922-004 Encube Ethicals, Inc. 1 TUBE in 1 CARTON (21922-004-07) / 60 g in 1 TUBE March 20, 2019
63629-8481 63629-8481 Bryant Ranch Prepack — March 20, 2019
63629-8482 63629-8482 Bryant Ranch Prepack — March 20, 2019
72162-1272 72162-1272 Bryant Ranch Prepack — March 20, 2019
21922-004 21922-004 Encube Ethicals, Inc. — March 20, 2019

Sources for this page

Every dataset that contributed a fact to this page.
Dataset Agency Used for
NDC Directory FDA Identity, ingredients, strengths, forms, routes, labelers, packages
Drugs@FDA FDA Application, sponsor, submissions, review documents, marketing status
Orange Book FDA Therapeutic equivalence codes, reference drug flags, patents, exclusivity
Drug Labeling FDA / NLM Prescribing information reproduced above
FAERS FDA Adverse event report counts

Generated September 25, 2026 · 11 sections on this page.